Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study

Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, Carlos Artigas, Camille Van Bogaert, Clémentine Marin, Rachele Danieli, Amelie Deleporte, Simona Picchia, Konstantinos Stathopoulos, Christiane Jungels, Bruno Vanderlinden, Marianne Paesmans, Lieveke Ameye, Gabriela Critchi, Loubna Taraji-Schiltz, Chloe Velghe, Zéna Wimana, Maria Bali, Alain Hendlisz, Patrick Flamen and Ioannis Karfis
Journal of Nuclear Medicine February 2024, 65 (2) 236-244; DOI: https://doi.org/10.2967/jnumed.123.265987
Magdalena Mileva
1Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gwennaëlle Marin
2Medical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugo Levillain
2Medical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Artigas
1Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camille Van Bogaert
3Nuclear Medicine Department, CUB-Hôpital Erasme, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clémentine Marin
2Medical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachele Danieli
2Medical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amelie Deleporte
4Medical Oncology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simona Picchia
5Radiology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantinos Stathopoulos
5Radiology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Jungels
4Medical Oncology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Vanderlinden
2Medical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Paesmans
6Data Center, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lieveke Ameye
6Data Center, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriela Critchi
1Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loubna Taraji-Schiltz
1Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chloe Velghe
6Data Center, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zéna Wimana
1Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
7Radiopharmacy Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Bali
5Radiology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Hendlisz
4Medical Oncology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Flamen
1Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioannis Karfis
1Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 65 no. 2 236-244
DOI 
https://doi.org/10.2967/jnumed.123.265987
PubMed 
38164576

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication May 9, 2023
  • Revision received October 25, 2023
  • Published online February 1, 2024.

Article Versions

  • previous version (December 21, 2023 - 07:47).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Magdalena Mileva1,
  2. Gwennaëlle Marin2,
  3. Hugo Levillain2,
  4. Carlos Artigas1,
  5. Camille Van Bogaert3,
  6. Clémentine Marin2,
  7. Rachele Danieli2,
  8. Amelie Deleporte4,
  9. Simona Picchia5,
  10. Konstantinos Stathopoulos5,
  11. Christiane Jungels4,
  12. Bruno Vanderlinden2,
  13. Marianne Paesmans6,
  14. Lieveke Ameye6,
  15. Gabriela Critchi1,
  16. Loubna Taraji-Schiltz1,
  17. Chloe Velghe6,
  18. Zéna Wimana1,7,
  19. Maria Bali5,
  20. Alain Hendlisz4,
  21. Patrick Flamen1 and
  22. Ioannis Karfis1
  1. 1Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  2. 2Medical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  3. 3Nuclear Medicine Department, CUB-Hôpital Erasme, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  4. 4Medical Oncology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  5. 5Radiology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium;
  6. 6Data Center, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; and
  7. 7Radiopharmacy Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
  1. For correspondence or reprints, contact Ioannis Karfis (ioannis.karfis{at}hubruxelles.be).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 21 Citations
  • 26 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
    Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki, Emmanuel Deshayes
    Journal of Nuclear Medicine 2024 65 6
  • A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
    Laure Vergnaud, Yuni K. Dewaraja, Anne-Laure Giraudet, Jean-Noël Badel, David Sarrut
    EJNMMI Physics 2024 11 1
  • Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update
    Martina Di Franco, Lucia Zanoni, Emilia Fortunati, Stefano Fanti, Valentina Ambrosini
    Current Oncology Reports 2024 26 5
  • Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
    Giulia Santo, Gianpaolo Di Santo, Irene Virgolini
    Seminars in Nuclear Medicine 2024 54 4
  • The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE
    Marco Maccauro, Mariarosaria Cuomo, Matteo Bauckneht, Matteo Bagnalasta, Stefania Mazzaglia, Federica Scalorbi, Giovanni Argiroffi, Margarita Kirienko, Alice Lorenzoni, Gianluca Aliberti, Sara Pusceddu, Calareso Giuseppina, Enrico Matteo Garanzini, Ettore Seregni, Carlo Chiesa
    European Journal of Nuclear Medicine and Molecular Imaging 2024 52 1
  • EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose–response and threshold absorbed doses
    Jean-Pierre Pouget, Pablo Minguez Gabina, Ken Herrmann, Desirée Deandreis, Mark Konijnenberg, David Taieb, Fijs W. B. van Leeuwen, Jens Kurth, Uta Eberlein, Michael Lassmann, Katharina Lückerath
    European Journal of Nuclear Medicine and Molecular Imaging 2025 52 3
  • Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients
    Onur Tuncer, Daniel Steinberger, Joseph Steiner, Madeleine Hinojos, Stephanie Y. Rhee, Brad Humphrey, Farhad Jafari, Zuzan Cayci
    Journal of Nuclear Medicine 2024 65 10
  • The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice
    Manuel Bardiès, Glenn Flux, Katarina Sjögreen Gleisner
    Journal of Nuclear Medicine 2024
  • 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review
    Caroline BOURSIER, Timothée ZARAGORI, Laëtitia IMBERT, Antoine VERGER
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2024 68 3
  • Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy
    Eonwoo Shin, Yong-il Kim, Changhoon Yoo, Yeokyeong Shin, Baek-Yeol Ryoo, Dong Yun Lee, Jin-Sook Ryu
    European Radiology 2024 35 5

Article usage

Article usage: December 2023 to April 2025

AbstractFullPdf
Dec 202361428665
Jan 2024652815285
Feb 2024573631188
Mar 2024166426139
Apr 2024105285113
May 20245466542
Jun 20245386237
Jul 202467613125
Aug 20247032762
Sep 20244323295
Oct 202453235102
Nov 20246126193
Dec 202442336136
Jan 202546361160
Feb 202549295108
Mar 20253925291
Apr 202542383171
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (2)
Journal of Nuclear Medicine
Vol. 65, Issue 2
February 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, Carlos Artigas, Camille Van Bogaert, Clémentine Marin, Rachele Danieli, Amelie Deleporte, Simona Picchia, Konstantinos Stathopoulos, Christiane Jungels, Bruno Vanderlinden, Marianne Paesmans, Lieveke Ameye, Gabriela Critchi, Loubna Taraji-Schiltz, Chloe Velghe, Zéna Wimana, Maria Bali, Alain Hendlisz, Patrick Flamen, Ioannis Karfis
Journal of Nuclear Medicine Feb 2024, 65 (2) 236-244; DOI: 10.2967/jnumed.123.265987

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, Carlos Artigas, Camille Van Bogaert, Clémentine Marin, Rachele Danieli, Amelie Deleporte, Simona Picchia, Konstantinos Stathopoulos, Christiane Jungels, Bruno Vanderlinden, Marianne Paesmans, Lieveke Ameye, Gabriela Critchi, Loubna Taraji-Schiltz, Chloe Velghe, Zéna Wimana, Maria Bali, Alain Hendlisz, Patrick Flamen, Ioannis Karfis
Journal of Nuclear Medicine Feb 2024, 65 (2) 236-244; DOI: 10.2967/jnumed.123.265987
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!
  • Multicycle Dosimetric Behavior and Dose-Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
  • Rethinking Dosimetry: A European Perspective
  • Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors
  • Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
  • Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects
  • The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice
  • Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients
  • Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Is Long–Axial-Field-of-View PET/CT Cost-Effective? An International Health–Economic Analysis
  • Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Show more Clinical Investigation

Similar Articles

Keywords

  • 68Ga-DOTATATE
  • neuroendocrine tumors
  • peptide receptor radionuclide therapy
  • response prediction
  • dosimetry
SNMMI

© 2025 SNMMI

Powered by HighWire